NCT05105607

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 (Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor) After Subcutaneous Administration in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Ashvattha Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to evaluate the safety and tolerability of D-4517.2 after single subcutaneous (SC) doses in healthy participants.

Conditions

• Neovascular Age-related Macular Degeneration
• Diabetic Macular Edema

Interventions

Type	Name	Description
DRUG	D-4517.2	Subcutaneous (SC) injection

Timeline

• Start date: 2022-01-11
• Primary completion: 2022-08-31
• Completion: 2022-08-31
• First posted: 2021-11-03
• Last updated: 2022-09-21

Locations

1 site across 1 country: Australia

Regulatory

• FDA-regulated drug study